Currentmedical mutual - ohioPolicy AHS - G2123

Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Customize your policy alerts

Sign up for medical mutual - ohio Policy AHS - G2123 alerts

Get alerted when Policy AHS - G2123 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines coverage criteria for cerebrospinal fluid and serum biomarker testing to aid diagnosis and evaluation of multiple sclerosis, NMOSD, and MOG-IgG–associated disease for Medical Mutual - Ohio beneficiaries and ordering providers.

Policy Summary

Payermedical mutual - ohio

PolicyBiomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Policy CodePolicy AHS - G2123

Change TypeTitle clarifiedcoding updates (added CPT 83884)literature review with no coverage change

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionWhen ordering CSF oligoclonal band testing, pair CSF with a serum sample and document atypical clinical, imaging, or laboratory features to support coverage.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentmedical mutual - ohioPolicy AHS - G2123

Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Customize your policy alerts

Sign up for medical mutual - ohio Policy AHS - G2123 alerts

Get alerted when Policy AHS - G2123 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payermedical mutual - ohio

PolicyBiomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Policy CodePolicy AHS - G2123

Change TypeTitle clarifiedcoding updates (added CPT 83884)literature review with no coverage change

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionWhen ordering CSF oligoclonal band testing, pair CSF with a serum sample and document atypical clinical, imaging, or laboratory features to support coverage.

SourceLink

POLICY UPDATE CHANGES

Title changed to include CSF and serum biomarkers; coding descriptions updated and CPT 83884 added (coding-only updates). Background and references updated without modifying coverage criteria.

OCB coveredOCB CSF testing covered

AQP4/MOG coveredAQP4 & MOG serum testing covered with criteria

Not coveredOther serum biomarker tests not covered

Assay exclusionsELISA/Western blot/IHC not covered for NMOSD/MOG-EM

1Off-cycle coding addition

No changeCoverage unchanged after review

Coverage Criteria for Biomarker Testing

CSF Oligoclonal Band Analysis - Covered Indications

CSF and serum oligoclonal band analysis meets coverage criteria when ANY of the following are present:

OCB covered indications: a) Atypical clinical, laboratory, or imaging features.

From policy: Section III, item 1a

OCB covered indications: b) Atypical clinically isolated syndrome, including but not limited to primary progressive multiple sclerosis or relapsing-remitting course.

From policy: Section III, item 1b

OCB covered indications: c) Individual belongs to a population in which MS is less common (for example, children or older individuals).

From policy: Section III, item 1c

OCB covered indications: d) Insufficient clinical or imaging evidence for diagnosis.

From policy: Section III, item 1d

Serum AQP4-IgG and MOG-IgG Testing - Covered Indications

Serum AQP4-IgG and MOG-IgG by indirect fluorescence assay or FACS meet coverage when ALL of the following are met:

AQP4/MOG testing criteria: 1) Individual has monophasic or relapsing acute optic neuritis, myelitis, brainstem encephalitis, encephalitis, or any combination thereof; 2) Radiological or electrophysiological findings compatible with central nervous system demyelination; 3) At least one of the following high-risk or supportive features: (i) belongs to a higher-risk population (e.g., pediatric), (ii) abnormal MRI with extensive optic nerve lesion, extensive spinal cord lesion or atrophy, or large confluent T2 brain lesions, (iii) prominent papilledema/papillitis/optic disc swelling during acute optic neuritis, (iv) neutrophilic CSF pleocytosis, (v) histopathology showing primary demyelination with intralesional complement and IgG deposits or previous 'pattern II MS' diagnosis, (vi) simultaneous bilateral acute optic neuritis, (vii) severe visual deficit or blindness during/after acute optic neuritis, (viii) severe or frequent episodes of acute myelitis or brainstem encephalitis, (ix) permanent sphincter and/or erectile disorder after myelitis, (x) previous diagnosis of acute disseminated encephalomyelitis (ADEM).

From policy: Section III, items 2a–2c and Table 1 recommendations

Not Covered - Serum Biomarker Tests and Certain Assay Methods

Tests that do not meet coverage criteria:

Not covered serum tests: All other serum biomarker tests for multiple sclerosis do NOT meet coverage criteria.

From policy: Section III, item 3

Not covered assay methods: ELISA, Western blot, immunohistochemistry, or any other serum assays to test for NMOSD or MOG-EM DO NOT MEET COVERAGE CRITERIA.

From policy: Section III, item 4 and IPND/IPND recommendations

Not Covered - Other CSF Biomarker Tests

Not covered CSF biomarkers: For the diagnosis of MS, NMOSD, or MOG-EM, all other cerebrospinal fluid biomarker tests, including AQP4-IgG or MOG-IgG in CSF, DO NOT MEET COVERAGE CRITERIA.

From policy: Section III, item 5

Guideline-based clinical indications and interpretation guidance

Guideline-based indications and testing recommendations (criteria reflect panel/guideline statements rather than an explicit payor decision in this excerpt):

CSF OCB testing: CSF examination for oligoclonal bands is strongly recommended when clinical and MRI evidence is insufficient for MS diagnosis, when presentation is atypical (including progressive onset), when considering initiation of long-term disease-modifying therapies, or in populations where MS is less common.CSF must be paired with serum

Panel: CSF OCBs can substitute for dissemination in time; specimen pairing required to demonstrate CSF-unique OCBs

AQP4 and MOG testing indications: AQP4 and MOG serological testing should be performed in patients with features suggesting NMOSD or MOG-EM (eg, LETM, bilateral optic neuritis, area postrema syndrome, normal brain MRI or MRI not fulfilling dissemination in space) and considered in higher-risk populations; cell-based serum assays (including FACS) are preferred.use serum CBA/FACS when possible

Confirmatory testing with different assay techniques recommended when initial results are low-titer or discordant

The policy explicitly excludes use of ELISA, Western blot, immunohistochemistry, or any other serum assay methods to test for neuromyelitis optica spectrum disorder (NMOSD) or MOG-IgG–associated encephalomyelitis (MOG-EM). Requests for these serum assay modalities do not meet coverage criteria and may be denied.

Because the pre-test probability of MOG-IgG is very low in patients with a progressive disease course, the policy follows guideline recommendations and does not support general MOG-IgG testing in progressive presentations. Routine screening in this population is not recommended.

This portion of the document does not list additional explicit exclusions beyond those described elsewhere in the policy text.

Serum biomarker tests for multiple sclerosis in situations not specified by the coverage criteria are considered not medically necessary. In other words, all other serum biomarker tests for MS do not meet coverage criteria as stated in the policy.

Peptide-based ELISA and Western blot for detection of MOG-IgG are specifically not recommended because they are considered insufficiently specific and effectively obsolete for primary diagnostic testing; the guideline prefers full-length human MOG cell-based assays (FACS/CBA) on serum.

No additional statements declaring tests as 'not medically necessary' appear in this revision segment beyond the previously described policy language and exclusions.

Applicable Procedure and Billing Codes

Applicable CPT/HCPCS Procedure CodesCPT

83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified.
83884	Neurofilament light chain (NfL) antigen; quantitative, not otherwise specified.
83916	Oligoclonal immune (oligoclonal bands).
84182	Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each.
86051	Aquaporin-4 (neuromyelitis optica [NMO]) antibody; enzyme-linked immunosorbent immunoassay (ELISA).
86362	Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; cell-based immunofluorescence assay (CBA), each.
88341	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.

Added/Updated CPT CodesCPT

83884

CPT code added (off-cycle coding modification)

Revised CPT CodesCPT

84182	CPT code description revised
0443U	CPT code description revised

Provider Responsibilities, Billing, and Documentation

Note

Coverage limitations and requirements

CSF oligoclonal band (OCB) analysis is covered only in specified clinical situations (atypical clinical/lab/imaging features; atypical clinically isolated syndrome including primary progressive or relapsing-remitting courses; populations in which MS is less common such as children or older individuals; or insufficient clinical or imaging evidence for diagnosis). Serum AQP4‑IgG and MOG‑IgG by indirect fluorescence assay or FACS are covered only when all stated clinical and radiologic/electrophysiologic criteria are met; all other serum biomarker tests and certain assay methods are not covered.

CSF/serum OCB analysis MEETS COVERAGE CRITERIA for individuals with atypical clinical, laboratory, or imaging features (chunk 3).
OCB testing MEETS COVERAGE CRITERIA for atypical clinically isolated syndrome, including primary progressive MS or relapsing‑remitting course (chunk 3).
OCB testing MEETS COVERAGE CRITERIA for populations where MS is less common (e.g., children, older individuals) or when clinical/MRI evidence is insufficient (chunk 4).
Serum AQP4‑IgG and MOG‑IgG by indirect fluorescence assay or FACS MEET COVERAGE CRITERIA only when all specified conditions (clinical syndrome, compatible radiology/electrophysiology, and ≥1 high‑risk feature) are present (chunk 4).
All other serum biomarker tests for MS DO NOT MEET COVERAGE CRITERIA (chunk 5).
ELISA, Western blot, immunohistochemistry, or other serum assays for NMOSD/MOG‑EM DO NOT MEET COVERAGE CRITERIA (chunk 5).
AQP4‑IgG or MOG‑IgG testing in CSF DO NOT MEET COVERAGE CRITERIA (chunk 5).

Clinical Background and Evidence Summary

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system with variable clinical presentations. Diagnosis relies primarily on demonstrating dissemination in time and space through clinical assessment and MRI, with cerebrospinal fluid oligoclonal IgG bands (OCBs) serving as a supportive diagnostic tool when clinical or imaging findings are atypical or insufficient. The policy aligns with guideline guidance that favors serum cell-based assays for AQP4-IgG and MOG-IgG and recommends pairing CSF OCB testing with a contemporaneous serum sample to demonstrate CSF-unique bands.

Key Definitions and Terms

OCB — definition and role of oligoclonal IgG bands in CSF testing for MS

DefinitionOligoclonal immunoglobulin G bands (OCBs) are discrete IgG bands detected in cerebrospinal fluid by isoelectric focusing and qualitative analysis, used to demonstrate intrathecal IgG synthesis.

Role in MS diagnosisCSF-specific OCBs support a diagnosis of multiple sclerosis and can substitute for dissemination in time when clinical/MRI evidence is insufficient.

Specimen requirementCSF analysis for OCBs should be paired with a serum sample to demonstrate that bands are unique to CSF.

Clinical indicationsRecommended when clinical or MRI evidence is insufficient, in atypical presentations (including progressive onset), or in populations where MS is less common (eg, children, older individuals).

AQP4-IgG / MOG-IgG — definition and diagnostic relevance for NMOSD and MOG-EM

Policy Revisions and Updates

2025-09-04literature_review_and_title_changeLatest

Literature review updated background, guidelines, and references; coverage criteria unchanged; title broadened to include CSF and serum biomarkers and CPT code descriptions for 84182 and 0443U were revised.

2024-12-04coding_update_off_cycle

Off-cycle coding modification added CPT code 83884 effective 2025-01-01.

Policy Summary

Payermedical mutual - ohio

PolicyBiomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Policy CodePolicy AHS - G2123

Change TypeTitle clarifiedcoding updates (added CPT 83884)literature review with no coverage change

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionWhen ordering CSF oligoclonal band testing, pair CSF with a serum sample and document atypical clinical, imaging, or laboratory features to support coverage.

SourceLink

On This Page

MOG-IgG testing guidance: Use full-length human MOG IgG-specific cell-based assays (FACS or CBA) on serum; avoid peptide ELISA, Western blot, and immunohistochemistry as primary tests; do not perform general MOG-IgG testing for progressive disease given low pre-test probability; retest during acute attacks or treatment-free intervals if initial negative and suspicion persists.serum specimen; timing: during acute attack or treatment-free interval

Recommendations reflect IPND guidance to limit overdiagnosis and inappropriate testing

sNfL use: Serum and CSF neurofilament light chain (NfL) correlate with disease activity: elevated in relapse and higher in relapsing versus progressive disease; age- and BMI-corrected percentiles or Z-scores are recommended for interpretation, and sNfL may decrease with effective therapies, supporting use of treatment context when interpreting serial values.age- and BMI-corrected reference percentiles/Z-scores recommended

Panel and evidence summarize clinical utility and interpretation considerations

Billing Rule

Billing codes reference

Use the applicable CPT/HCPCS procedure codes listed in the policy when ordering and billing for biomarker tests; the policy provides code-level references for neurofilament, OCB, AQP4/MOG assays, and related procedures for provider billing guidance.

Refer to the policy's applicable CPT/HCPCS codes section for codes such as 83520, 83884, 83916, 84182, 86051, 86362, and 88341 as listed (chunk 33).
Procedure codes in policy documents are provided as a general reference and may not be all‑inclusive (chunk 34).

Billing Rule

Coding updates; no prior authorization change stated

Coding descriptions were updated and a CPT code was added, but the policy segment does not introduce any new prior authorization requirements or changes to prior‑auth logic.

Off‑cycle coding modification added CPT code 83884 (effective 1/1/2025) and CPT descriptions for 84182 and 0443U were revised (chunk 43).
The revision history notes coding updates without changes to coverage criteria or prior authorization requirements (chunk 43).

Note

No additional provider action specified in this segment.

Note

Consider therapy context when interpreting sNfL

When interpreting serial serum neurofilament light chain (sNfL), consider the patient's therapy context: Z‑scores decreased to control levels with monoclonal antibody treatments, decreased to a lesser extent with oral therapies, and did not decrease with platform therapies.

sNfL Z scores decreased with monoclonal antibodies and less so with oral therapies; no decrease was seen with platform compounds such as interferons and glatiramer acetate (chunk 19).
Interpret sNfL percentiles/Z‑scores with age‑ and BMI‑corrected reference values as noted in the policy (chunk 19).

Step Therapy

No step therapy requirements specified

The policy does not specify any step therapy requirements for biomarker testing in this section.

Revision history and coverage sections do not state step therapy requirements (chunk 43).

Documentation Required

Required clinical documentation to justify covered testing

Document clinical justification to support covered testing; records should show atypical clinical, laboratory, or imaging features (including atypical CIS, populations with lower MS prevalence, or insufficient clinical/MRI evidence) or, for NMOSD/MOG‑EM testing, compatible clinical syndromes and at least one high‑risk feature.

For CSF OCB testing, document atypical clinical, laboratory, or imaging features; atypical clinically isolated syndrome; membership in a population where MS is less common; or insufficient clinical/imaging evidence (chunks 3, 4).
For serum AQP4‑IgG/MOG‑IgG testing, document the clinical syndrome (optic neuritis, myelitis, brainstem encephalitis, encephalitis), compatible radiologic/electrophysiologic findings, and at least one listed high‑risk feature (chunk 4).
Include paired serum with CSF when requesting OCB testing to demonstrate CSF‑unique oligoclonal bands as required by guidance (chunk 23).

Documentation Required

Specimen pairing required for OCB testing

When ordering CSF oligoclonal band analysis, submit a paired serum sample so laboratories can demonstrate CSF‑unique OCBs.

The International Panel emphasizes that CSF must be paired with a serum sample to demonstrate that OCBs are unique to CSF (chunk 23).

Documentation Required

No specific prior‑auth documentation forms provided in this segment

This policy excerpt does not include explicit prior authorization paperwork or additional clinical record templates beyond the documentation guidance above.

The revision history and policy text do not introduce specific prior authorization documentation forms or requirements in this segment (chunk 43).

Denial Risk

Denial triggers for non‑covered assays

Requests for serum biomarker tests for multiple sclerosis in other situations, and requests using ELISA, Western blot, immunohistochemistry or other excluded serum assay methods for NMOSD/MOG‑EM, do not meet coverage criteria and may be denied.

All other serum biomarker tests for MS DO NOT MEET COVERAGE CRITERIA (chunk 5).
ELISA, Western blot, immunohistochemistry, or any other serum assays for NMOSD or MOG‑EM DO NOT MEET COVERAGE CRITERIA (chunk 5).

Denial Risk

Conflict with government policy may change coverage outcome

If this policy conflicts with applicable government coverage policies (e.g., LCDs or NCDs), the government policy will govern and may result in different coverage outcomes.

The policy states that in case of conflict with relevant government policies, the government policy will be used to make the determination (chunk 31).

Denial Risk

No new denial triggers introduced by coding changes

No additional explicit denial triggers are provided in this segment; the changes noted were administrative coding updates and did not change coverage criteria.

Revision history confirms coding updates without changes to coverage criteria (chunk 43).
Policy text identifies specific non‑covered tests and methods that may lead to denial (chunk 5).

AQP4-IgG and MOG-IgG are serum autoantibodies directed against aquaporin-4 and myelin oligodendrocyte glycoprotein, respectively, used to identify NMOSD and MOG-associated encephalomyelitis (MOG-EM).

Diagnostic relevancePresence of AQP4-IgG supports neuromyelitis optica spectrum disorder (NMOSD); MOG-IgG supports MOG-EM and both inform diagnosis and prognosis (eg, optic neuritis severity).

Testing contextSerologic testing is recommended for patients with acute optic neuritis, myelitis, brainstem encephalitis, encephalitis, or compatible radiologic/electrophysiologic findings and selected high‑risk features.

Neurofilament light chain (NfL) — biomarker measurable in CSF and serum correlated with neuroaxonal injury and disease activity

DefinitionNeurofilament light chain (NfL) is a neuronal structural protein measurable in cerebrospinal fluid and serum that reflects neuroaxonal injury.

Correlation with disease activityElevated CSF and serum NfL levels correlate with MS activity and relapse; higher levels observed in relapsing versus progressive disease in meta-analysis.

Evidence baseMeta-analysis (Martin et al.) and additional longitudinal studies link higher NfL to active disease and worse long-term outcomes, supporting its clinical validity as a biomarker of neuronal injury.

OCB / IgG index — CSF-specific oligoclonal bands and IgG index indicate intrathecal IgG synthesis and support MS diagnosis

DefinitionCSF-specific oligoclonal bands (OCBs) are discrete IgG bands in CSF absent from paired serum; the IgG index quantifies intrathecal IgG synthesis.

Diagnostic implicationPresence of CSF-unique OCBs supports MS diagnosis and is an independent predictor of risk for a second clinical attack.

IgG index thresholdAn IgG index >0.7 has very high positive predictive value (>99%) for the presence of OCBs based on cohort data.

Cell-based assay (CBA) — recommended assay methodology for detecting AQP4-IgG and MOG-IgG with higher sensitivity/specificity

DefinitionCell-based assays (CBA) use live cells expressing full-length human antigen (eg, full-length MOG or AQP4) to detect specific autoantibodies, often read by microscopy or flow cytometry (FACS).

Recommended methodologyCBA/FACS is the preferred testing modality for AQP4-IgG and MOG-IgG because it provides higher sensitivity and specificity than peptide ELISA, Western blot, or immunohistochemistry.

Confirmatory testingConfirmatory testing with alternative assay techniques is recommended when initial results are low-titer or discordant; specialized laboratories may be required for optimal assay performance.

AQP4 and MOG autoantibodies — role in diagnosing NMOSD and MOG-EM

Role in diagnosisAQP4 and MOG autoantibodies are used to help diagnose NMOSD and MOG-EM and to distinguish these disorders from multiple sclerosis.

Clinical implicationsAQP4-IgG seropositivity is associated with characteristic clinical syndromes (eg, severe optic neuritis, longitudinally extensive transverse myelitis) and worse visual outcomes compared with MOG-IgG or MS.

Testing considerationsCell-based serum assays are recommended whenever possible; ELISA and some indirect assays have lower sensitivity and require interpretative caution and confirmatory testing when positive at low titer.

Neurofilament light chain (NfL) — prognostic biomarker measurable in serum or CSF associated with neuronal injury and long-term outcomes

DefinitionNeurofilament light chain (NfL) is a fluid biomarker measurable in serum or CSF that indicates neuronal injury and axonal degeneration.

Prognostic valueHigher sNfL/CSF NfL levels are associated with increased risk of future disease activity and worse long-term outcomes; sNfL percentiles/Z-scores improve individual prognostication.

Use with therapy contextSerial sNfL levels decrease with higher-efficacy therapies (eg, monoclonal antibodies) and should be interpreted considering recent treatments and timing relative to attacks or interventions.